GlassScriptPhysician profile
Vadak Ranganathan
NPI 1992773212
$2,117.47
in general payments reported to CMS, 2019-2025
33 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $302 · 2021: $261 · 2022: $372 · 2023: $221 · 2024: $226 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598 · Education: $66.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.81 |
| Education | $66.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $230.62 | 2019-2023 | Trintellix |
| Abbvie INC. | $214.98 | 2021-2025 | |
| Ucb, INC. | $197.94 | 2021-2025 | Briviact, Nayzilam |
| Biogen, INC. | $182.01 | 2019-2024 | Vumerity, Tysabri |
| Eisai INC. | $176.64 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $130.52 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $115.24 | 2019-2020 | |
| Pfizer INC. | $88.33 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $77.68 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $73.08 | 2025 | Rexulti |
| Catalyst Pharmaceuticals, INC. | $66.88 | 2024 | |
| Genzyme Corporation | $63.97 | 2019-2022 | |
| Greenwich Biosciences, INC. | $62.04 | 2021 | |
| Vanda Pharmaceuticals INC. | $46.69 | 2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $46.36 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $42.88 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $27.70 | 2022-2023 | Ongentys, Ingrezza |
| Lilly USA, LLC | $26.98 | 2022-2023 | Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $25.67 | 2022 | |
| Neurelis, INC. | $25.41 | 2023 | Valtoco |
| Sk Life Science, INC. | $17.87 | 2022 | |
| Emd Serono, INC. | $17.56 | 2024 | |
| Mdd US Operations, LLC | $16.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.26 | 2019 | |
| Merz Pharmaceuticals, LLC | $16.14 | 2025 | Inbrija |
| Lundbeck LLC | $15.84 | 2023 | Vyepti |
| Ge Healthcare | $15.11 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.86 | 2019 | |
| Livanova USA, INC. | $14.16 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceuticals, INC. | $13.54 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.44 | 2022 | |
| Celgene Corporation | $12.20 | 2021 | |
| Scilex Pharmaceuticals INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vadak Ranganathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.